Youn Jung Lee

Youn Jung Lee

Auto-generated profile, based on publicly available information

Youn Jung Lee

Department of Psychiatry, Gyeongsang National University Hospital, Jinju, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Current Psychiatry Reports
Verified
Journal Article
Closed access
PDF file
YLYounjung Lee
Younjung Lee
Yong-Ku KimYong-Ku Kim
Yong-Ku Kim

1 October 2021 in Journal of the Korean Academy of Child and Adolescent Psychiatry
Verified
Journal Article
Open access
PDF file
JLJi Won Lee
Ji Won Lee
BKBong Jo Kim
Bong Jo Kim
CLCheol-Soon Lee
Cheol-Soon Lee
BCBoseok Cha
Boseok Cha
SLSo-Jin Lee
So-Jin Lee
JCJae-Won Choi
Jae-Won Choi
Ji Won Lee, Bong-Jo Kim, Cheol-Soon Lee, Boseok Cha, So-Jin Lee, Dongyun Lee, Jiyeong Seo, Young-Ji Lee, Youn-Jung Lee, Eunji Lim, and Jae-Won Choi. J Korean Acad Child Adolesc Psychiatry 2021;32:161-9. https://doi.org/10.5765/jkacap.210024

1 May 2021 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
CSCheolmin Shin
Cheolmin Shin
CPChi-Un Pae
Chi-Un Pae
KKKyung Phil Kwak
Kyung Phil Kwak
SJSang-Won Jeon
Sang-Won Jeon
HJHyun-Ghang Jeong
Hyun-Ghang Jeong
CHChangsu Han
Changsu Han
Objective: Many patients with major depressive disorder (MDD) suffer from residual symptoms without achieving remission. However, pharmacologic options for residual symptoms of MDD have been limited. This study aimed to investigate benefit of aripiprazole augmentation in the treatment of residual symptoms in the patients with partially remitted MDD. Methods: We retrospectively analyzed the 8-week medical records of the patients. The enrolled patients did respond to treatment of antidepressant but were not remitted. The range of 17-item Hamilton Depression Rating Scale (HAMD) total score of the subjects were 8 to 15 points. All patients were currently taking antidepressants when they started aripiprazole. The primary endpoint was the mean change of Clinically Useful Depression Outcome Scale (CUDOS). Secondary endpoint measures were HAMD, Clinical Global Impression-severity (CGI-S) scores, Patient Health Questionnaire-15 (PHQ-15), Beck Anxiety Inventory (BAI), Perceived Deficit Questionnaire-depression (PDQ-D), Sheehan Disability Scale (SDS) and General Health Questionnaire/Quality of Life-12 (GHQ/QL-12). Results: A total of 134 medical records were analyzed. The changes of CUDOS, HAMD, CGI-S, BAI, PHQ-15, PDQ-D, SDS and GHQ/QL-12 from baseline to the endpoint were -7.93, -3.29, -0.80, -4.02, -2.05, -4.35, -4.77 and -2.82, respectively (all p < 0.001). At the endpoint, the newly remitted subjects rate by HAMD score criteria were approximately 46%. Conclusion: Our preliminary findings have presented the effectiveness of aripiprazole augmentation for residual symptoms of partially remitted MDD patients in routine practice. This study assures subsequent well-controlled studies of the possibility of generalizing the above promising outcome in the future.

25 October 2020 in Psychiatry Investigation
Verified
Journal Article
Open access
PDF file
KCKwang-Yeon Choi
Kwang-Yeon Choi
JCJeong Min Choo
Jeong Min Choo
YLYoun-Jung Lee
Youn-Jung Lee
YLYujin Lee
Yujin Lee
CCChul-Hyun Cho
Chul-Hyun Cho
HLHeon-Jeong Lee
Heon-Jeong Lee
Objective Interleukin-10 (IL-10) is a major immunoregulatory cytokine and its gene plays a fundamental role in anti-inflammatory and immunosuppressive activity. This study aimed to examine the association between the IL10 gene promoter -1082G/A polymorphism (rs1800896) and tardive dyskinesia (TD) in schizophrenia.Methods Two hundred and eighty unrelated Korean schizophrenic patients participated in this study (105 TD and 175 non-TD patients). TD was diagnosed using the Research Diagnostic Criteria for TD and Abnormal Involuntary Movement Scale (AIMS). Genotyping was performed by RT-PCR and high-resolution melting curve analysis.Results The distributions of genotypic frequencies did not differ between patients with and without TD (χ2=4.33, p=0.115). However, allelic frequencies of the two groups were different (χ2=4.45, p=0.035); the A allele frequency was higher in TD. The total AIMS scores of the three genotypes were not different (F=1.33, p=0.266). However, the total AIMS scores of the A allele carrier and the A allele non-carrier were significantly different (t=5.79, p<0.001). Logistic regression analaysis showed that IL10 -1082G/A genotype significantly predicts presence of TD (p=0.045) after adjusting for covariates such as age and treatment duration.Conclusion This finding suggests that the A allele of rs1800896 may be associated with TD development following a low IL-10 function.

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
IAIn-Young Ahn
In-Young Ahn
BKBong Jo Kim
Bong Jo Kim
CLCheol-Soon Lee
Cheol-Soon Lee
BCBoseok Cha
Boseok Cha
SLSo-Jin Lee
So-Jin Lee
DLDongyun Lee
Dongyun Lee
Lee YJ, et al. J Korean Med Sci. 2021 Mar;36(11):e73. https://doi.org/10.3346/jkms.2021.36.e73

31 December 2020 in Chronobiology in Medicine
Verified
Journal Article
Open access
PDF file
YLYounjung Lee
Younjung Lee
CCChul-Hyun Cho
Chul-Hyun Cho
HLHeon-Jeong Lee
Heon-Jeong Lee